Key Summary Points {#FPar1}
==================

**Why carry out this study?**Real-world data from biologic experienced patients on the effectiveness of golimumab are sparse.In clinical practice, agents are needed that are suitable independent of the patient pre-treatment status.The non-interventional, prospective study assessed golimumab used as first, second, or at least third biologic agent in RA, PsA and AS in a real-world setting.**What was learned from this study?**Golimumab is an effective treatment in patients with RA, PsA, and AS, irrespective of pre-treatment with biologic agents.After failure of previous TNFi it is appropriate to switch to an alternative TNFi despite the fact that the sequential drug targets the same molecular and inflammatory pathways.

Introduction {#Sec1}
============

The TNF inhibitor (TNFi) golimumab (GLM) was shown to be effective and well tolerated in the randomized clinical trials (RCT) used for registration \[[@CR1]--[@CR3]\] and in their open-label 5-year extensions \[[@CR4]--[@CR6]\]. These trials were limited to patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who did not have any treatment with a biologic prior to GLM.

Also, in the placebo-controlled RCT GO-AFTER study of RA patients who had an inadequate response to at least one TNFi, GLM administered subcutaneously (SC) reduced the signs and symptoms of the disease \[[@CR7]\]. The extension of this study demonstrated the safety and efficacy of golimumab treatment for 5 years in some patients \[[@CR8]\].

The EULAR guidelines for the management of RA recommend that if one TNFi therapy has failed, patients may receive another TNFi or an agent with another mode of action \[[@CR9]\]. Similarly, the updated EULAR guidelines for axial spondyloarthritis recommend switching to another TNFi or an anti-IL-17 if TNFi therapy fails \[[@CR10]\]. Finally, for the management of PsA in patients who fail to respond adequately to a biologic DMARD, EULAR recommends that a switch to another TNFi or biologic DMARD should be considered \[[@CR11]\]. Current US guidelines for PsA and AS provide similar recommendations \[[@CR12], [@CR13]\].

Data on the sequential application of one TNFi after another are limited, as are data from real-world settings that compare biologic-naïve and biologic-experienced patients. Against this background, the aim of this post hoc analysis was to assess the effectiveness of GLM used as a first-, second-, or at least third-line biologic agent in RA, PsA, and AS in a real-life setting in Germany.

The non-Interventional Clinical Evaluation with Golimumab (GO-NICE) study, was chosen for this analysis. This 2-year study confirmed the effectiveness and safety of GLM 50 mg SC once monthly in patients with RA, PsA, and AS in a real-life setting in Germany. Substantial improvements in disease activity as measured by DAS28 in RA patients and by BASDAI in AS patients, and in clinical response as measured by PsARC in PsA patients, were seen early at 3 months and were maintained throughout the 24-month observation period, in line with previous clinical studies \[[@CR14]\]. Further, substantial improvements in patient-reported quality of life, functional capacity, and fatigue were documented in a very similar manner for the three conditions mentioned above, and these improvements were maintained throughout the 24-month observation period \[[@CR15]\].

The aim of this post hoc analysis was to assess the effectiveness of GLM used as a first-, second-, or at least third-line biologic agent in RA, PsA, and AS in a real-world setting.

Methods {#Sec2}
=======

GO-NICE was a prospective, multicenter, noninterventional study performed at 158 sites throughout Germany. Details on the rationale, methods, and design of this study have been reported previously \[[@CR14], [@CR15]\]. In brief, after providing their informed consent, adult patients with established rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who were started on GLM 50 mg subcutaneously once monthly between April 2010 and September 2015 were enrolled. For each patient, GLM was prescribed by the treating physician based on the patient's need for GLM therapy, and in accordance with the summary of product characteristics \[[@CR16]\]. The decision to initiate GLM treatment was made independently of data documentation and prior to the inclusion of the patient in this study.

Patients were assessed at treatment initiation and every 3 months thereafter for 2 years (resulting in a total of up to 9 visits). Clinical effectiveness in patients with RA was assessed according to the standard of care using the 28-Joint Disease Activity Score (DAS28) based on the erythrocyte sedimentation rate (ESR) \[[@CR17], [@CR18]\]. In patients with PsA, the Psoriatic Arthritis Response Criteria (PsARC) index was used to assess joint and skin involvement \[[@CR19], [@CR20]\], and in patients with AS, the 10-Point Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to categorize disease activity \[[@CR21]\].

Patient-reported outcomes were assessed through quality-of-life questionnaires (EQ-5D-3L), functional ability (FFbH), and fatigue (FACIT) \[[@CR15]\].

In the present post hoc analysis, patients were grouped by number of previous biologic treatments into those using GLM as a first-line biologic treatment (no pretreatment with a biologic agent; biologic-naïve patients), those using GLM as a second-line treatment (i.e., after one previous biologic agent), and those using GLM as at least a third-line treatment (i.e., after at least two previous biologic agents). The analysis was descriptive; *p* values were calculated with chi-square tests. The endpoint measures DAS28-ESR, PsARC, and BASDAI are shown as observed. There was no imputation of missing values for any parameter.

The study was performed in accordance with the Declaration of Helsinki and the standards of Good Clinical Practice. Primary ethics approval was obtained from the Ethics Committee of Ludwig Maximilian University in Munich on 17 February 2010 (number 008--10). All patients provided their written informed consent prior to participation.

The ClinicalTrials.gov identifier is NCT01313858.

Results {#Sec3}
=======

Patient disposition during the study course is shown in Fig. [1](#Fig1){ref-type="fig"}. GLM was administered as a first-line (*n* = 305, 286, 292, respectively), a second-line (*n* = 104, 136, 130, respectively), or at least a third-line (*n* = 64, 79, 58, respectively) biologic agent in 1454 patients with RA, PsA, or AS. Biologic agents used in previous treatments included adalimumab (*n* = 348), etanercept (*n* = 287), infliximab (*n* = 139), tocilizumab (*n* = 27), rituximab (*n* = 15), certolizumab (*n* = 14), and abatacept (*n* = 12).Fig. 1Patient disposition

The proportion of biologic-naïve patients who completed the study on their GLM treatment was higher than the corresponding proportions of patients on second- and at least third-line GLM treatment in all three subgroups.

Among the patients using GLM as the first-, second-, and at least third-line biologic agent, 43.0%, 30.8%, and 39.1%, respectively, of the patients with RA; 53.1%, 38.2%, and 34.2%, respectively, of the patients with PsA; and 53.8%, 49.2%, and 41.4%, respectively, of the patients with AS completed the study (i.e., remained on the treatment until month 24).

The baseline and demographic characteristics of the patients are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the RA, PsA, and AS patients by line of treatmentCharacteristicLine of treatmentRA\
*n* = 473 (100.0%)PsA\
*n* = 501 (100.0%)AS\
*n* = 480 (100.0%)Number of patients1st line305 (64.5%)286 (57.0%)292 (60.8%)2nd line104 (22.0%)136 (27.1%)130 (27.1%)At least 3rd line64 (13.5%)79 (15.8%)58 (85.3%)Completers (24 months of treatment, 9 visits)1st line131 (40.6%)152 (50.3%)157 (49.1%)2nd line32 (27.8%)52 (35.4%)64 (44.8%)At least 3rd line25 (34.2%)27 (30.3%)24 (35.3%)Mean age, years (range)1st line55.0 ± 13.6 (20--82)50.0 ± 12.442.5 ± 12.42nd line55.7 ± 13.1 (20--81)50.7 ± 11.945.3 ± 12.3At least 3rd line53.4 ± 13.0 (19--79)50.7 ± 11.544.8 ± 11.2Proportion of males1st line86 (28.2%)131 (45.8%)207 (70.9%)2nd line30 (28.8%)70 (51.5%)82 (63.1%)At least 3rd line13 (20.3%)29 (36.7%)31 (53.4%)Mean body mass index, kg/m^2^ (range)1st line26.3 ± 4.7 (17.0--61.3)27.8 ± 5.3 (16.7--48.5)26.7 ± 5.0 (18.2--56.1)2nd line27.3 ± 5.4 (20.3--53.1)28.6 ± 5.7 (15.6--55.4)26.6 ± 4.6 (18.0--42.6)At least 3rd line26.3 ± 4.8 (17.6--39.6)28.3 ± 5.4 (17.6--42.9)27.2 ± 6.0 (16.4--48.4)Employed full-time or part-time1st line142 (46.7%)172 (61.4%)219 (75.3%)2nd line48 (46.1%)66 (48.9%)78 (60.0%)At least 3rd line26 (40.6%)40 (50.7%)37 (63.8%)Time since first diagnosis, years (range)1st line9.7 ± 8.7 (0.3--59.3)12.4 ± 12.0 (0.1--62.0)9.4 ± 9.7 (0.0--49.2)2nd line10.1 ± 8.4 (0.7--48.6)13.7 ± 11.0 (0.3--56.9)9.8 ± 8.6 (0.5--47.1)At least 3rd line14.3 ± 10.0 (1.5--43.6)13.8 ± 10.3 (0.1--43.8)12.4 ± 9.3 (1.2--48.7)Rheumatoid factor positive (RF +)1st line233 (76.9%)2nd line73 (70.2%)At least 3rd line38 (59.4%)CCP antibody positive (ccp +)1st line230 (76.2%)2nd line80 (78.4%)At least 3rd line36 (59.0%)HLA-B27 positive1st line237 (81.2%)2nd line105 (80.8%)At least 3rd line43 (74.1%)Extraarticular manifestation1st line45 (14.8%)251 (88.1%)91 (31.2%)2nd line17 (16.3%)122 (89.7%)46 (35.9%)At least 3rd line11 (17.2%)66 (83.5%)25 (43.1%)Tender joints, *n*1st line8.2 ± 6.87.3 ± 6.42nd line8.2 ± 6.98.0 ± 11.1At least 3rd line9.8 ± 8.49.0 ± 8.0Swollen joints, *n*1st line5.9 ± 5.04.0 ± 4.32nd line5.5 ± 5.23.8 ± 5.2At least 3rd line6.4 ± 6.64.9 ± 6.8Systemic glucocorticoids1st line86 (28.2%)75 (26.6%)11 (3.8%)2nd line24 (23.1%)27 (19.9%)6 (4.6%)At least 3rd line19 (29.7%)23 (29.1%)2 (3.4%)NSAR, COX-2 inhibitors, analgesics1st line93 (30.5%)123 (43.6%)193 (66.1%)2nd line31 (29.9%)53 (38.9%)70 (53.8%)At least 3rd line29 (45.3%)53 (67.1%)49 (56.5%)Values are the mean ± standard deviation or the number of patients (percentage)

*Rheumatoid arthritis (n* = *473 patients)*. Mean age was 55.0, 55.7, and 53.4 years in the RA patients who used GLM as the first-, second-, and at least third-line treatment, respectively. Rheumatoid factor was positive in 76.9%, 70.2%, and 59.4%, CCP antibody was positive in 76.2%, 78.4%, and 59.0%, and time since first diagnosis was 9.7, 10.1, and 14.3 years in those patients, respectively.

DAS28 score at BL was 5.0, 4.9, and 5.1 in the RA patients who used GLM as the first-, second-, and at least third-line treatment, respectively, and decreased significantly over time in those three subgroups (Fig. [2](#Fig2){ref-type="fig"}). After 3 months of treatment, 27.5%, 19.5%, and 14.5% of those patients were in remission (DAS28 \< 2.6), and 45.3%, 50.0%, and 33.3% were in remission after 24 months, respectively (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Disease activity (DAS28) in RA patients during treatment with golimumab as the first-, second-, or at least third-line biologic agent. BL, baseline; DAS28, Disease Activity Score, 28 joints; RA, rheumatoid arthritis. In patients with RA the 28-joint Disease Activity Score (DAS28) based on erythrocyte sedimentation rate was used to categorise disease activityFig. 3Percentages of RA patients with high disease activity (DAS28) or in remission during treatment with golimumab as the first-, second-, or at least third-line biologic agent. HDA: DAS28\>5.1, remission: DAS28 \<2.6; DAS28, Disease Activity Score, 28 joints; HDA, high disease activity; RA, rheumatoid arthritis

*Psoriatic arthritis (n* = *501 patients)*. Mean age was 50.0, 50.7, and 50.7 years in PsA patients who used GLM as the first-, second-, and at least third-line treatment, respectively. Time since first diagnosis was 12.4, 13.7, and 13.8 years in those patients, respectively. A response (based on PsARC) was achieved at 24 months in 76.4%, 51.0%, and 50.0% of the PsA patients who used GLM as the first-, second-, and at least third-line treatment, respectively (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Percentages of PsA patients who responded (according to PsARC) to golimumab used as a first-, second-, or at least third-line biologic agent. PsARC, Psoriatic Arthritis Response Criteria in Patients with PsA, the Psoriatic Arthritis Response Criteria (PsARC) index was used to assess joint and skin involvement

*Ankylosing spondylitis (n* = *480 patients)*. Mean age was 42.5, 45.3, and 44.8 years and time since first diagnosis was 9.4, 9.8, and 12.4 years in AS patients who used GLM as the first-, second-, and at least third-line treatment, respectively. 81.2%, 80.8%, and 74.1% of AS patients were HLAB27 positive, respectively. At baseline, 162 AS patients had extraarticular manifestations: 31.2%, 35.9%, and 43% of the AS patients who used GLM as the first-, second-, and at least third-line treatment, respectively. The most common manifestations of inflammation were iritis, enthesitis, irritable bowel disease, and dactylitis.

AS patients with at least two previous biologic DMARDs had a somewhat higher BASDAI at BL than AS patients who were using GLM as the first- or second-line treatment: 5.7 vs. 5.0 and 4.9. After 24 months of treatment, the mean BASDAI scores decreased significantly (*p* \< 0.001 vs. BL) to 2.1, 2.9, and 2.9 in AS patients who used GLM as the first-, second-, and at least third-line treatment, respectively (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Disease activity (BASDAI) in AS patients who used golimumab as first-, second-, or at least third-line biologic agent. AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Index; BL, baseline in patients with AS, the 10-point Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to categorise disease activity

Discussion {#Sec4}
==========

In this noninterventional study of patients with RA, PsA, and AS, GLM therapy was found to be an effective treatment. Notable improvements in DAS28 and BASDAI were observed with GLM treatment in all three subgroups. Better outcomes were achieved in biologic-naïve patients, especially in patients with PsA, than in second-line therapy, and to a somewhat lesser effect in third-line therapy.

Our findings are in line with several retrospective or observational studies that investigated the value of second-line GLM therapy in various indications.

In retrospectively collected data from four academic centers in Greece, patients with various inflammatory arthritides that were treated with GLM showed a high 3-year long-term survival on drug, with a low rate of discontinuation due to AEs \[[@CR22]\]. The survival on drug (SOD) of 328 patients with RA, PsA, and AS treated with GLM at 2 and 3 years was 68% and 62% overall, respectively. The study found that there was no difference in survival on drug between biologic-naïve and biologic-experienced patients, nor between non-biologic-cotreated and GLM monotherapy-treated patients.

Data from the Italian cohort of the LORHEN multicentric registry also provide evidence that second-line GLM is effective over time, with an advantage over adalimumab and etanercept \[[@CR23]\]. In 195 RA patients who failed a previous TNFi treatment, the 2-year retention rate (40%, with a median time on drug of 12.9 months across the whole population) was significantly lower for adalimumab (31.2%, *p* = 0.018) and numerically lower for etanercept (39.8%) than for GLM (53.4%) because of a higher discontinuation rate due to adverse events versus GLM. According to the authors, their real-life data showed that switching to a second TNFi is a good option for treating RA patients who failed their first-line TNFi treatment, especially when the second TNFi is used in combination with synthetic DMARDs \[[@CR23]\].

In a Swedish retrospective study of 845 patients with immune-mediated rheumatic diseases, a high persistence with second-line GLM was documented \[[@CR24]\]. Specifically, GLM exhibited statistically significantly higher persistence than adalimumab and numerically greater persistence than etanercept and certolizumab pegol at 36 months of follow-up, which agrees with results observed for first-line SC TNFi treatment.

According to a recently published systematic literature review \[[@CR25]\], in 12 real-world studies comparing various TNFi treatments of immune-mediated rheumatic diseases, GLM persistence was found to be significantly better than or equal to the persistence of its comparators. In conclusion, overall GLM persistence (regardless of treatment line) at 24 months approximated 50%, with a lower persistence in AS (43%) patients than in RA and PsA.

When discussing study outcomes, it is important to note some limitations of the GO-NICE study. This study has an observational design. In contrast to a randomized controlled trial, this design allows for the documentation of typical patients under real-life conditions and therefore has high external validity and is generalizable to clinical practice. However, one major limitation of this study is the relatively high rate of patients lost to follow-up, meaning that there is no information on their outcomes \[[@CR14]\].

The Ankylosing Spondylitis Disease Activity Score (ASDAS) \[[@CR26]\] was not assessed in this study, as GO-NICE was initiated in 2010 under clinical practice conditions, at which point ASDAS was yet to be validated in Germany. The relatively long follow-up time of 2 years is informative with respect to the duration of the effect on work outcomes and other parameters. Due to the absence of a control group in our study, regression to the mean must be taken into consideration as a cause of improvement because patients are likely to initiate biological agents when the disease flares \[[@CR27]\]. Also, we cannot exclude the possibility that the results are no different from the expected course of intensive DMARD treatment \[[@CR27]\]. Due to the heterogeneity of health care systems and legislation, treatment patterns, and societal effects among countries, great caution should be exercised when extrapolating our results to countries or settings outside Germany.

Conclusion {#Sec5}
==========

In conclusion, the present analysis confirms that it is appropriate to switch to an alternative TNFi after the failure of a previous TNFi treatment, despite the fact that the alternative TNFi targets the same molecular and inflammatory pathways. While the present analysis of GO-NICE does not permit a comparison of the various TNFis, it supports the use of GLM in various lines of therapy for the three inflammatory rheumatic diseases.

**Digital Features:**To view digital features for this article go to: 10.6084/m9.figshare.12005502.
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